Latest news with #SrikripaDevarakonda
Business Insider
30-07-2025
- Business
- Business Insider
Incyte (INCY) Gets a Hold from Truist Financial
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Incyte, with a price target of $79.00. The company's shares closed today at $77.38. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Devarakonda covers the Healthcare sector, focusing on stocks such as Scholar Rock Holding, Incyte, and Nurix Therapeutics. According to TipRanks, Devarakonda has an average return of 0.4% and a 44.12% success rate on recommended stocks. In addition to Truist Financial, Incyte also received a Hold from William Blair's Matt Phipps in a report issued today. However, on the same day, TD Cowen maintained a Buy rating on Incyte (NASDAQ: INCY). The company has a one-year high of $83.95 and a one-year low of $53.56. Currently, Incyte has an average volume of 1.83M. Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Earlier this month, Steven H Stein, the EVP & Chief Medical Officer of INCY sold 3,706.00 shares for a total of $251,785.64.
Yahoo
07-07-2025
- Business
- Yahoo
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), lowering the price target to $10 from $28. A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform. The firm released its updated outlook on the company after the latter released its fiscal Q1 2025 results. AbCellera Biologics Inc. (NASDAQ:ABCL) reported $4.2 million in total revenue for the quarter, generating a net loss of $45.6 million compared to net loss of $40.6 million last year. It also reached a cumulative total of 97 partner-initiated program starts with downstreams. The analyst told investors in a research note that the firm is continuing to have a positive outlook for AbCellera Biologics Inc. (NASDAQ:ABCL), citing the continued execution of its wholly owned clinical pipeline. Since the company is shifting the focus of its hybrid business model to a clinical-stage biotech, the firm updated its discount rate to account for the transition. AbCellera Biologics (NASDAQ:ABCL) solves antibody discovery problems by integrating data science, technology, infrastructure, and interdisciplinary teams. It develops and discovers antibody medicines for indications across therapeutic areas, including metabolic and endocrine conditions, cancer, and autoimmune disorders. It boasts technology platforms that unlock drug classes, modalities, and targets, including T-cell engagers, peptide-MHCs, and transmembrane proteins. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Insider
17-06-2025
- Business
- Business Insider
Truist Financial Keeps Their Buy Rating on Nurix Therapeutics (NRIX)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report). The company's shares closed yesterday at $11.96. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Devarakonda covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Regeneron, and Scholar Rock Holding. According to TipRanks, Devarakonda has an average return of -0.8% and a 43.48% success rate on recommended stocks. In addition to Truist Financial, Nurix Therapeutics also received a Buy from BTIG's Jeet Mukherjee in a report issued today. However, on June 3, Leerink Partners reiterated a Hold rating on Nurix Therapeutics (NASDAQ: NRIX).
Business Insider
03-06-2025
- Business
- Business Insider
Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price target of $53.00. Confident Investing Starts Here: According to TipRanks, Devarakonda is an analyst with an average return of -5.9% and a 32.60% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Regeneron, and Scholar Rock Holding. In addition to Truist Financial, Kymera Therapeutics also received a Buy from Citi's Geoff Meacham in a report issued today. However, yesterday, Morgan Stanley maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). Based on Kymera Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.1 million and a GAAP net loss of $65.58 million. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $48.56 million Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year. Most recently, in March 2025, Jeremy Chadwick, the COO of KYMR sold 1,383.00 shares for a total of $42,103.92.
Reuters
02-06-2025
- Business
- Reuters
Regeneron's weight-loss drug combo helps preserve muscle in study
June 2 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday a combination of its experimental drug and Novo Nordisk's ( opens new tab obesity drug Wegovy helped patients lose weight while preserving lean muscle mass in a mid-stage trial. The combination of Regeneron's drug, trevogrumab, and Wegovy helped preserve up to 51.3% of the lean mass after 26 weeks, compared with 34.5% loss when Wegovy was administered alone, according to interim data from the 599-patient study. The results mark an early win for Regeneron as it races against a dozen companies to develop obesity treatments that preserve muscle, as they seek to find the next breakthrough in the potential $150 billion weight-loss drug market. Blockbuster weight-loss drugs from Novo Nordisk and Eli Lily (LLY.N), opens new tab have helped patients shed fat, but also led to muscle loss that can increase the risk of falls and decrease overall strength, which could be especially harmful for older patients. Wegovy helped patients shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass, while the combination of Regeneron's trevogrumab and Wegovy led to weight loss of about 21.6 pounds, with only 3.7 pounds in lean mass. "While we wait for detailed data, we believe that these data give a glimpse into the potential for these drugs to preserve muscle," said Truist analyst Srikripa Devarakonda. Meanwhile, a triple combination of Novo's semaglutide, Regeneron's trevogrumab and experimental antibody garetosmab led to a substantially higher rate of discontinuation due to tolerability issues and other side effects, Regeneron said. The full data set will be available later this year, the drugmaker said. Regeneron on Monday announced a licensing deal worth up to $2.01 billion with China's Hansoh Pharmaceuticals ( opens new tab for an experimental obesity drug.
